Evidence map›Paper›PMID 39409887›Full record

ReviewCancers2024

The Multimodality Management of Malignant Peripheral Nerve Sheath Tumours.

Remus Seres, Hassan Hameed, Martin G McCabe, David Russell, Alexander T J Lee

Abstract readReview
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Malignant triton tumor of the common bile duct.Clinical journal of gastroenterology · 2025
    Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Remus SeresDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.
Hassan HameedDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.
Martin G McCabeDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.ORCID 0000-0002-5138-0707
David RussellDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, UK.
Alexander T J LeeDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant peripheral nerve sheath tumours (MPNST) are aggressive sarcomas that have nerve sheath differentiation and can present at any anatomical site. They can arise from precursor neurofibroma in the context of neurofibromatosis type 1 (NF1) or as de novo and sporadic tumours in the absence of an underlying genetic predisposition. The primary therapeutic approach is most often radical surgery, with non-surgical modalities playing an important role, especially in locally advanced or metastatic cases. The aim of multimodality approaches is to optimize both local and systemic control while keeping to a minimum acute and late treatment morbidity. Advances in the understanding of the underlying biology of MPNSTs in both sporadic and NF-1-related contexts are essential for the management and implementation of novel therapeutic approaches.

Indexed as

malignant peripheral nerve sheath tumourmolecular alterationsmultimodality managementnerveneurofibromaneurofibromatosis type 1

Identifiers

PMID39409887
PMCPMC11475700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.